trial

Digoxin Drug-Drug Interaction With Lurasidone HCl

NCTId NCT01082289
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 24 (actual)
Sponsored by Sumitomo Pharmaceuticals America
Primary completion 2008-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
24 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
—
Start
2008-09
Primary completion
2008-10
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Lurasidone

Sponsors

Sumitomo Pharmaceuticals AmericaLead Sponsor

Investigators

1
Marina Bussel, MDPrincipal Investigator

Sites

1 total
Culver City, United States

Facts & assertions

4 sourced
Enrollment
24
Phase
PHASE1
Primary Completion Date
2008-10
Status
COMPLETED
relationships
The graph out of here
drug
Lurasidone
drug
lead_sponsor
Sumitomo Pharmaceuticals America
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Marina Bussel, MD
person